The drug too has lost steam in the global market with the World Health Organisation (WHO) suspending the HCQ arm of its Solidarity trial again this week. Some clinicians have observed that there was no benefit from the drug in reducing death.
WHO had suspended the trials once before too. Emergency Use Authorisation of the drug was also revoked in the US recently.
In the domestic market, India sold over 220 million tablets since March, according to industry estimates. The government has picked up stock for 100 million tablets by April. Each patient requires either five to nine tablets. Going by that, the stock would last for months as it can cater to about 10 million people.
India had banned exports of the drug that was touted as a miracle drug for Covid19. India continues to use it as a prophylactic against covid19 in healthcare workers and immediate caregivers to patients.
In April US President Donald Trump had threatened retaliation if the drug was not supplied to US. Since April India has been exporting the drug to many countries including the US.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.